LXRX - Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.
Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. “We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts,” said Mike Exton, Ph.D.
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones.
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.39 and traded as high as $1.66. Lexicon Pharmaceuticals shares last traded at $1.51, with a volume of 3,357,632 shares trading hands. Wall Street Analysts Forecast Growth
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Oncotelic Therapeutics (OTCMKTS:OTLC - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Profitability This table compares Oncotelic Therapeutics and
THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The congress is being held March 11-14, 2026, in Barcelona, Spain.
Lexicon Pharmaceuticals (NASDAQ: LXRX) outlined progress across three late-stage programs and reported sharply lower operating expenses during its fourth-quarter and full-year 2025 earnings call held March 5, 2026. Management emphasized near-term regulatory and clinical milestones for sotagliflozin in type 1 diabetes and hypertrophic cardiomyopathy (HCM), continued partnering efforts for the chronic pain candidate pilavapadin, and milestone-driven
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments. “The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,” said Mike Exton, Ph.D.
THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m.
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, March 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) Director Raymond Debbane acquired 100,000 shares of the business's stock in a transaction on Friday, February 20th. The shares were purchased at an average price of $1.48 per share, for a total transaction of $148,000.00. Following the transaction, the director directly owned 1,804,186 shares of the company's